Healthcare Industry News: ViaCell
News Release - January 22, 2007
ViaCell Appoints Kirk Williamson as Vice President of Marketing
CAMBRIDGE, Mass.--(HSMN NewsFeed)--ViaCell, Inc. (Nasdaq: VIAC ) today announced that Kirk T. Williamson joined the Company as Vice President of Marketing. Mr. Williamson will have overall responsibility for marketing initiatives related to ViaCell's reproductive health business, including ongoing marketing efforts for ViaCord®, a product offering for the preservation of stem cells from umbilical cord blood, and potential new product opportunities."Kirk is an accomplished executive with extensive expertise in management and marketing. His experiences from leading healthcare and consumer focused companies including Bristol-Myers Squibb and Gillette will be of significant value and we are extremely pleased to welcome him to ViaCell," said Mr. Jim Corbett, President, ViaCell Reproductive Health.
Mr. Williamson joins ViaCell from The Gillette Company where he served as Vice President and General Manager for the Oral-B Professional Products Group. In this role he led a $100 million, 130-member North American professional sales and marketing team with responsibility for all marketing, sales, business development, professional affairs, trade planning and promotion initiatives. Previously, he was Director of Consumer Marketing at Bristol-Myers Squibb where he directed the creation and execution of consumer marketing strategies and programs. Mr. Williamson also held a variety of sales and marketing positions at Frito-Lay, Inc. He holds a Bachelor of Science degree in Business Administration from Bucknell University and a Masters in Business Administration from the University of North Carolina, Chapel Hill.
About ViaCell
ViaCell is a biotechnology company focused on enabling the widespread use of human cells as medicine. The Company is developing a pipeline of proprietary stem cell product candidates intended to address cancer, cardiac disease, and diabetes. CB001, its lead cord blood derived stem cell therapy product candidate, is being developed for hematopoietic stem cell transplantation in patients affected by a variety of cancers. In addition to its therapeutic development programs, ViaCell's Reproductive Health Business commercializes ViaCord®, a product that offers expecting families the option of preserving their baby's umbilical cord blood. The Company is working to leverage its commercial infrastructure and product development capabilities by developing ViaCyte(SM), its investigational product intended to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell is headquartered in Cambridge, Massachusetts with a processing and storage facility in Kentucky and additional research and development operations in Singapore. Additional information about ViaCell is available online at http://www.ViaCellinc.com.
ViaCell® and ViaCord® are federally registered trademarks and ViaCyte(SM) is a service mark of ViaCell, Inc.
Source: ViaCell
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!